Efficacy Signal but Failure to Meet Internal Investment Criteria

Spyre Therapeutics (SYRE) announced on August 25, 2026, the results of the SKYWAY Phase 2 trial for the rheumatoid arthritis (RA) cohort and deprioritized the development of SPY072 monotherapy. SPY072, a long-acting monoclonal antibody in clinical development under a code name without a brand or international nonproprietary name, is designed to inhibit T-cell-mediated inflammation by blocking Tumor Necrosis Factor-Like Ligand 1A (TL1A). While pharmacological activity was demonstrated, management determined that the efficacy magnitude was insufficient to justify late-stage clinical development and commercialization in the highly competitive RA market.

Only Low Dose Met Primary Endpoint

A total of 143 patients with moderate-to-severe active RA were randomly assigned to high-dose (48 patients), low-dose (48 patients), or placebo (47 patients) groups and evaluated over 12 weeks. The change in the Disease Activity Score 28-CRP (DAS28-CRP) at week 12 was -1.5 points for the high-dose group, -1.9 points for the low-dose group, and -1.3 points for the placebo group, with only the low-dose group achieving statistical significance (p<0.05) compared to placebo. ACR20 response rates were 63%, 58%, and 43%, and ACR50 rates were 31%, 38%, and 19%, respectively. However, the high-dose group showed an inverted dose-response and limited placebo correction, weakening the monotherapy's differentiation. Both doses fully and durably suppressed free TL1A over 12 weeks, suggesting the results reflect the efficacy ceiling of monotherapy targeting TL1A in RA rather than inadequate drug exposure.

Safety Was Maintained, but Stock Fell 13%

Adverse event rates were 27% in the treatment groups and 36% in the placebo group, with most being mild or moderate. No drug-related serious adverse events occurred. Infection rates were 14% in the treatment groups and 15% in the placebo group, indicating that safety was not the reason for the development halt. However, the stock price fell 13% the following day, erasing over $1 billion in market capitalization, as the company's valuation had previously exceeded $90 billion with significant expectations for RA expansion success.

Competition with Existing Therapies and anti-TL1A Agents

Standard RA treatment begins with disease-modifying antirheumatic drugs (DMARDs) such as methotrexate and progresses to biological or targeted synthetic therapies like Humira (adalimumab, TNF-α) and Rinvoq (upadacitinib, JAK1). The U.S. FDA approved Humira for adult RA on December 31, 2002, and Rinvoq on August 16, 2019. Given the availability of well-established therapies and biosimilars, new mechanisms face high efficacy thresholds. In the anti-TL1A space, Merck & Co. (MRK)'s Phase 3 tulisokibart (MK-7240) and Roche (RHHBY)'s Phase 3 afimkibart (RVT-3101) are leading in inflammatory bowel disease, highlighting the importance of indication selection over mechanism for SPY072's mixed RA results.

Follow-Up Data Will Be a Pivotal Point for Platform Value

Spyre plans to release Phase 2 SKYWAY results for SPY072 in psoriatic arthritis and axial spondyloarthritis in Q4 2026, with SKYLIGHT data on combination with IL-17A/F inhibitors in onychomycosis targeting late 2027 or early 2028. The global RA treatment market is projected to grow from $28.3 billion in 2026 to $45.2 billion by 2033, but this decision has ended SPY072's path to enter the market as a monotherapy. Merck's acquisition of Prometheus Biosciences for approximately $10.8 billion and Roche's upfront payment of $710 million and milestones of $150 million to Telavant underscore that TL1A asset value depends heavily on strong clinical differentiation.